Yale launches massive heart failure registry to monitor Real-World care
NCT ID NCT04237701
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study creates a live registry of up to 40,000 heart failure patients across the Yale New Haven Health System. Researchers will track hospitalizations and use of recommended therapies like beta blockers and ACE inhibitors. The goal is to monitor and improve heart failure care in real time, without testing any new drug or device.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help doctors better understand and track heart failure care, potentially improving treatment guidelines and patient outcomes.
- What could go wrong
- This is an observational registry, not a treatment trial. It cannot directly test new therapies, and results may not apply to patients outside the Yale system.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2019
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Seen within the Yale New Haven Health System * Diagnosis of heart failure Exclusion Criteria: * Age\<18
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Yale New Haven Health System
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can biomarkers predict which elderly heart failure patients will return to hospital?
- Can a daily pill shield hearts in HFpEF?
- Can an inhaler boost heart pumping in COPD patients?
- Can zapping the heart beat drugs for AF in heart failure?
- Could a handheld ultrasound help clinics spot heart failure sooner?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin